Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.86 USD
Change Today +0.0095 / 1.12%
Volume 351.3K
IBIO On Other Exchanges
Symbol
Exchange
Berlin
NYSE Amex
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

ibio inc (IBIO) Snapshot

Open
$0.86
Previous Close
$0.85
Day High
$0.89
Day Low
$0.82
52 Week High
10/17/14 - $3.48
52 Week Low
05/27/14 - $0.24
Market Cap
63.6M
Average Volume 10 Days
1.5M
EPS TTM
$-0.08
Shares Outstanding
74.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IBIO INC (IBIO)

Related News

No related news articles were found.

ibio inc (IBIO) Related Businessweek News

No Related Businessweek News Found

ibio inc (IBIO) Details

iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates comprise IBIO-CFB03, a product for treatment of idiopathic pulmonary fibrosis; C1 Esterase Inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement protein; and Palivizumab, a monoclonal antibody for the therapeutic protein market. Its vaccine products include H1N1 Influenza and H5N1 Influenza products that have completed Phase I human clinical trials, as well as yellow fever vaccine; malaria and hookworm parasitic pathogen vaccines; and human papillomavirus therapeutic vaccine. The company’s product candidates also comprise Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody for the biodefense market. It has strategic alliances and collaborations with various companies, such as Fraunhofer Center for Molecular Biology, GE Healthcare, FioCruz, and Caliber Biotherapeutics LLC. The company is headquartered in Newark, Delaware.

7 Employees
Last Reported Date: 09/29/14

ibio inc (IBIO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $300.0K
President
Total Annual Compensation: $230.0K
Chief Financial Officer
Total Annual Compensation: $22.0K
Chief Scientific Officer
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2014.

ibio inc (IBIO) Key Developments

iBio, Inc. announced delayed 10-Q filing

On 02/17/2015, iBio, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Levi & Korsinsky Announces Class Action Lawsuit iBio, Inc

Levi & Korsinsky announced that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. securities between October 13, 2014 and October 23, 2014. The complaint alleges that during the class period, the company issued materially false and misleading statements to investors by wrongfully suggesting that the company's launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The complaint alleges that when the true facts were revealed, the price of the company's stock fell significantly, damaging investors.

iBio, Inc., Annual General Meeting, Dec 10, 2014

iBio, Inc., Annual General Meeting, Dec 10, 2014., at 10:00 US Eastern Standard Time. Location: Omni Berkshire Place Hotel, 21 East 52 Street. Agenda: To elect two directors each to serve as Class III directors for a three year term expiring at the 2017 annual meeting of stockholders or until successors have been duly elected and qualified; to ratify the appointment of CohnReznick LLP as the company's independent registered public accounting firm for the fiscal year ending June 30, 2015; to approve an advisory vote on executive compensation; and to transact any other business properly brought before the annual meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBIO:US $0.86 USD +0.0095

IBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBIO.
View Industry Companies
 

Industry Analysis

IBIO

Industry Average

Valuation IBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.9x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBIO INC, please visit www.ibioinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.